Abstract: The present invention relates to a particularly advantageous new therapeutic use of melflufen (melphalan flufenamide; L-melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof: in the treatment or prophylaxis of multiple myeloma in a patient having multiple myeloma who:—has not received a stem cell transplant; or—has received a stem cell transplant that was at least 5 years ago; or—is 75 years old or older; or—has not received a stem cell transplant and is 75 years old or older, or has received a stem cell transplant that was at least 5 years ago and is 75 years old or older; or—has received a stem cell transplant and the disease subsequently progressed at least 36 months after the transplant. The inventors have found that melflufen, and in particular melflufen in combination with dexamethasone, is surprisingly effective for the treatment or prophylaxis of multiple myeloma in these patients.

Abstract: An agricultural implement includes ground engaging tools, connected to an attachment frame via a linkage arrangement and a fluid control system. For each ground engaging tool there is a linear actuator to provide a supplemental down force to the ground engaging tool via the linkage arrangement. The linear actuators are adapted so that the same relation between the rod chamber control pressure and the cap chamber control pressure causes first linear actuators to provide a first supplemental down force, and second linear actuators to provide a larger second supplemental down force. This enables a higher supplemental down force to be applied to row units behind the tractor wheels, although the fluid control system supplies the same relation between the rod and cap chamber control pressures to all linear actuators.

Abstract: An agricultural implement (1) for soil working, comprising a frame (10, 101, 10a, 10b, 10c, 10d, 10e), a number of ground-engaging tools (12, 13) carried by the frame, at least one rolling ground support (11a, 11b), the height position of which is adjustable relative to the frame, a height sensor (31) for contact-free measuring of the height position of the frame relative to a ground surface (G1), and a control unit (15), arranged to receive a signal from the height sensor (31) and to control the height position of the rolling ground support (11a, 11b). At least one of the tools (12, 13) is resilient relative to the frame (10, 101, 10a, 10b, 10c, 10d, 10e). A tool position sensor (32) is arranged to measure the orientation of the tool (12, 13), and the control unit (15) is arranged to receive a signal from the tool position sensor (32) and to calculate a work depth for said tool (12, 13) based on the signal from the height sensor (31) and based on the signal from the tool position sensor (32).

Abstract: The invention provides melflufen, or a salt thereof, or a pharmaceutical formulation comprising melflufen, or a salt thereof, for use in the treatment and/or prophylaxis of immunoglobulin light chain (AL) amyloidosis. The invention also provides dosage regimens and kits that find utility in the treatment and/or prophylaxis of AL amyloidosis, and methods for the treatment and/or prophylaxis of AL amyloidosis, and uses of melflufen, or a salt thereof, for the manufacture of a medicament for the treatment of AL amyloidosis.

Abstract: The present invention provides melflufen (melphalan flufenamide; L-Melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min).

Abstract: The present invention providesmelflufen (melphalan flufenamide; L-Melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min).